RT Journal Article
SR Electronic
T1 Cross-border transmissions of delta substrain AY.29 during Olympic and Paralympic Games
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.31.21265711
DO 10.1101/2021.10.31.21265711
A1 Koyama, Takahiko
A1 Tokumasu, Reitaro
A1 Katayama, Kotoe
A1 Saito, Ayumu
A1 Kudo, Michiharu
A1 Imoto, Seiya
YR 2021
UL http://medrxiv.org/content/early/2021/11/01/2021.10.31.21265711.abstract
AB Tokyo Olympic and Paralympic Games, postponed for COVID-19 pandemic, were finally held in summer of 2021. Just before the games, alpha variant was being replaced with more contagious delta variant (B.1.617.2). AY.4 substrain AY.29, which harbors two additional characteristic mutations of 5239C>T (NSP3 Y840Y) and 5514T>C (NSP3 V932A), emerged in Japan and became the dominant strain in Tokyo by the time of the Olympic Games. As of October 18, 98 AY.29 samples are identified in 16 countries outside of Japan. Phylogenetic analysis and ancestral searches identified 46 distinct introductions of AY.29 strains into those 16 countries. United States has 44 samples with 10 distinct introductions, and United Kingdom has 13 distinct AY.29 strains introduced in 16 samples. Other countries or regions with multiple introductions of AY.29 are Canada, Germany, South Korea, and Hong Kong while Italy, France, Spain, Sweden, Belgium, Peru, Australia, New Zealand, and Indonesia have only one distinct strain introduced. There exists no unambiguous evidence that Olympic and Paralympic Games induced cross-border transmission of the delta substrain AY.29. Since most of unvaccinated countries are also under sampled for genome analysis with longer lead time for data sharing, it will take longer to capture the whole picture of cross-border transmissions of AY.29.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available SARS-CoV-2 genome data which was isolated from human. The data can be obtained from: NCBI: https://www.ncbi.nlm.nih.gov/ GISAID: https://www.gisaid.org/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genome data used in the study is listed in supplemental table and available at GISAID and NCBI. COVID-19 case and death number in japan is available at Our World in Data. https://www.gisaid.org/ https://ourworldindata.org/ https://www.ncbi.nlm.nih.gov/ List of AbbreviationsCOVID-19Coronavirus Disease 2019SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2GISAIDGlobal initiative on sharing all influenza dataIOCInternational Olympic CommitteeIPCInternational Paralympic CommitteeVoCVariant of ConcernVoIVariant of InterestWHOWorld Health OrganizationHarumi OV/PVHarumi Olympic Village / Paralympic Village